» Articles » PMID: 18669912

Embryonic Stem Cell Therapy of Heart Failure in Genetic Cardiomyopathy

Overview
Journal Stem Cells
Date 2008 Aug 2
PMID 18669912
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Pathogenic causes underlying nonischemic cardiomyopathies are increasingly being resolved, yet repair therapies for these commonly heritable forms of heart failure are lacking. A case in point is human dilated cardiomyopathy 10 (CMD10; Online Mendelian Inheritance in Man #608569), a progressive organ dysfunction syndrome refractory to conventional therapies and linked to mutations in cardiac ATP-sensitive K(+) (K(ATP)) channel subunits. Embryonic stem cell therapy demonstrates benefit in ischemic heart disease, but the reparative capacity of this allogeneic regenerative cell source has not been tested in inherited cardiomyopathy. Here, in a Kir6.2-knockout model lacking functional K(ATP) channels, we recapitulated under the imposed stress of pressure overload the gene-environment substrate of CMD10. Salient features of the human malignant heart failure phenotype were reproduced, including compromised contractility, ventricular dilatation, and poor survival. Embryonic stem cells were delivered through the epicardial route into the left ventricular wall of cardiomyopathic stressed Kir6.2-null mutants. At 1 month of therapy, transplantation of 200,000 cells per heart achieved teratoma-free reversal of systolic dysfunction and electrical synchronization and halted maladaptive remodeling, thereby preventing end-stage organ failure. Tracked using the lacZ reporter transgene, stem cells engrafted into host heart. Beyond formation of cardiac tissue positive for Kir6.2, transplantation induced cell cycle activation and halved fibrotic zones, normalizing sarcomeric and gap junction organization within remuscularized hearts. Improved systemic function induced by stem cell therapy translated into increased stamina, absence of anasarca, and benefit to overall survivorship. Embryonic stem cells thus achieve functional repair in nonischemic genetic cardiomyopathy, expanding indications to the therapy of heritable heart failure. Disclosure of potential conflicts of interest is found at the end of this article.

Citing Articles

Brachyury engineers cardiac repair competent stem cells.

Li M, Yamada S, Shi A, Singh R, Rolland T, Jeon R Stem Cells Transl Med. 2020; 10(3):385-397.

PMID: 33098750 PMC: 7900595. DOI: 10.1002/sctm.20-0193.


Modeling Cardiac Disease Mechanisms Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Progress, Promises and Challenges.

Parrotta E, Lucchino V, Scaramuzzino L, Scalise S, Cuda G Int J Mol Sci. 2020; 21(12).

PMID: 32575374 PMC: 7352327. DOI: 10.3390/ijms21124354.


Regenerative therapies in young hearts with structural or congenital heart disease.

Michel-Behnke I, Pavo I, Recla S, Khalil M, Jux C, Schranz D Transl Pediatr. 2019; 8(2):140-150.

PMID: 31161081 PMC: 6514281. DOI: 10.21037/tp.2019.03.01.


Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart.

Yadav S, Mishra P J Vis Exp. 2019; (143).

PMID: 30663680 PMC: 7207148. DOI: 10.3791/58448.


The march of pluripotent stem cells in cardiovascular regenerative medicine.

Abou-Saleh H, Zouein F, El-Yazbi A, Sanoudou D, Raynaud C, Rao C Stem Cell Res Ther. 2018; 9(1):201.

PMID: 30053890 PMC: 6062943. DOI: 10.1186/s13287-018-0947-5.


References
1.
Lila N, Amrein C, Guillemain R, Chevalier P, Latremouille C, Fabiani J . Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation. 2002; 105(16):1949-54. DOI: 10.1161/01.cir.0000015075.89984.46. View

2.
He J, Ma Y, Lee Y, Thomson J, Kamp T . Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res. 2003; 93(1):32-9. DOI: 10.1161/01.RES.0000080317.92718.99. View

3.
Faustino R, Behfar A, Perez-Terzic C, Terzic A . Genomic chart guiding embryonic stem cell cardiopoiesis. Genome Biol. 2008; 9(1):R6. PMC: 2395240. DOI: 10.1186/gb-2008-9-1-r6. View

4.
Pouly J, Hagege A, Vilquin J, Bissery A, Rouche A, Bruneval P . Does the functional efficacy of skeletal myoblast transplantation extend to nonischemic cardiomyopathy?. Circulation. 2004; 110(12):1626-31. DOI: 10.1161/01.CIR.0000142861.55862.15. View

5.
Behfar A, Perez-Terzic C, Faustino R, Arrell D, Hodgson D, Yamada S . Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med. 2007; 204(2):405-20. PMC: 2118723. DOI: 10.1084/jem.20061916. View